Detalhe da pesquisa
1.
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life.
Sci Rep
; 11(1): 3173, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33542437